Chewy Inc vs Incyte Corporation — how do they compare? Chewy Inc trades at $22.59 (market cap $9.15B), while Incyte Corporation trades at $120.55 (market cap $24.48B). The key difference: Incyte Corporation is far larger — about 2.7× Chewy Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Chewy Inc nearer its low. Which is the better fit depends on your goals.
| CHWY | INCY | |
|---|---|---|
Market Cap | $9.15B | $24.48B |
Sector | Consumer Cyclical | Health |
52-Week High | $42.33 | $129.93 |
52-Week Low | $17.51 | $81.66 |
Enterprise Value | $9.11B | $19.98B |
Trailing returns across standard periods
Chewy is the largest e-commerce pet care retailer in the U.S., generating $8.9 billion in 2021 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a standalone company in 2019, after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods, like crates, leashes, and bowls.
Read more on CHWY →Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →